FDA Approves ZYRTEC — Kenvue Brands LLC

Kenvue Brands LLC has confirmed the continued availability of ZYRTEC (cetirizine hydrochloride), a global allergy leader initially approved by the FDA in 2004, signaling stability for the massive cetirizine market as major generic competitors intensify. While this confirmation helps stabilize brand premium pricing against a rising tide of generic alternatives, it underscores Kenvue’s strategy of preserving patient adherence through established brand recognition despite intensified competitive pricing pressure.